These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 19326117)

  • 1. 18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer.
    Duch J; Fuster D; Muñoz M; Fernández PL; Paredes P; Fontanillas M; Guzmán F; Rubí S; Lomeña FJ; Pons F
    Eur J Nucl Med Mol Imaging; 2009 Oct; 36(10):1551-7. PubMed ID: 19326117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET/CT with [18F] fluorodeoxyglucose in the assessment of metabolic response to neoadjuvant chemotherapy in locally advanced breast cancer.
    Duch J; Fuster D; Muñoz M; Fernández PL; Paredes P; Fontanillas M; Skaltsa K; Domènech B; Lomeña F; Pons F
    Q J Nucl Med Mol Imaging; 2012 Jun; 56(3):291-8. PubMed ID: 22695339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycolytic activity with 18F-FDG PET/CT predicts final neoadjuvant chemotherapy response in breast cancer.
    García Vicente AM; Cruz Mora MÁ; León Martín AA; Muñoz Sánchez Mdel M; Relea Calatayud F; Van Gómez López O; Espinosa Aunión R; Gonzalez Ageitos A; Soriano Castrejón A
    Tumour Biol; 2014 Nov; 35(11):11613-20. PubMed ID: 25139100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer.
    Groheux D; Hindié E; Giacchetti S; Hamy AS; Berger F; Merlet P; de Roquancourt A; de Cremoux P; Marty M; Hatt M; Espié M
    Eur J Cancer; 2014 Jul; 50(11):1864-71. PubMed ID: 24841218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can FDG-PET/CT predict early response to neoadjuvant chemotherapy in breast cancer?
    Andrade WP; Lima EN; Osório CA; do Socorro Maciel M; Baiocchi G; Bitencourt AG; Fanelli MF; Damascena AS; Soares FA
    Eur J Surg Oncol; 2013 Dec; 39(12):1358-63. PubMed ID: 24120422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.
    Cheng J; Wang Y; Mo M; Bao X; Zhang Y; Liu G; Zhang J; Geng D
    Oncotarget; 2015 Oct; 6(30):29388-95. PubMed ID: 26336821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of interim 18F-FDG PET/CT in predicting early response to neoadjuvant chemotherapy in breast cancer.
    Pahk K; Rhee S; Cho J; Seo M; Lee S; Park T; Park S; Lee E; Park KH; Kim C; Eo JS; Kim S; Choe JG
    Anticancer Res; 2014 Aug; 34(8):4447-55. PubMed ID: 25075084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison between 18F-FDG PET image-derived indices for early prediction of response to neoadjuvant chemotherapy in breast cancer.
    Hatt M; Groheux D; Martineau A; Espié M; Hindié E; Giacchetti S; de Roquancourt A; Visvikis D; Cheze-Le Rest C
    J Nucl Med; 2013 Mar; 54(3):341-9. PubMed ID: 23327900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive and prognostic potential of volume-based metabolic variables obtained by a baseline
    Garcia-Vicente AM; Pérez-Beteta J; Amo-Salas M; Molina D; Jimenez-Londoño GA; Soriano-Castrejón AM; Pena Pardo FJ; Martínez-González A
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(2):73-79. PubMed ID: 29102649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring of neoadjuvant chemotherapy using multiparametric, ²³Na sodium MR, and multimodality (PET/CT/MRI) imaging in locally advanced breast cancer.
    Jacobs MA; Ouwerkerk R; Wolff AC; Gabrielson E; Warzecha H; Jeter S; Bluemke DA; Wahl R; Stearns V
    Breast Cancer Res Treat; 2011 Jul; 128(1):119-26. PubMed ID: 21455671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET.
    Dose Schwarz J; Bader M; Jenicke L; Hemminger G; Jänicke F; Avril N
    J Nucl Med; 2005 Jul; 46(7):1144-50. PubMed ID: 16000283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype.
    Groheux D; Majdoub M; Sanna A; de Cremoux P; Hindié E; Giacchetti S; Martineau A; de Roquancourt A; Merlet P; Visvikis D; Resche-Rigon M; Hatt M; Espié M
    Radiology; 2015 Nov; 277(2):358-71. PubMed ID: 25915099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging--prospective assessment.
    Tateishi U; Miyake M; Nagaoka T; Terauchi T; Kubota K; Kinoshita T; Daisaki H; Macapinlac HA
    Radiology; 2012 Apr; 263(1):53-63. PubMed ID: 22438441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer.
    Groheux D; Sanna A; Majdoub M; de Cremoux P; Giacchetti S; Teixeira L; Espié M; Merlet P; de Roquancourt A; Visvikis D; Hatt M; Resche-Rigon M; Hindié E
    J Nucl Med; 2015 Jun; 56(6):824-31. PubMed ID: 25883123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential FDG-PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemo-radiation therapy.
    Capirci C; Rampin L; Erba PA; Galeotti F; Crepaldi G; Banti E; Gava M; Fanti S; Mariani G; Muzzio PC; Rubello D
    Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1583-93. PubMed ID: 17503039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting Response to Neoadjuvant Chemotherapy Using 18F FDG PET-CT in Patients with Locally Advanced Breast Cancer.
    Hulikal N; Gajjala SR; Kalawat T; Kadiyala S; Kottu R
    Asian Pac J Cancer Prev; 2020 Jan; 21(1):93-98. PubMed ID: 31983170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study.
    Ueda S; Tsuda H; Saeki T; Omata J; Osaki A; Shigekawa T; Ishida J; Tamura K; Abe Y; Moriya T; Yamamoto J
    Breast Cancer; 2011 Oct; 18(4):299-308. PubMed ID: 20617404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy.
    Groheux D; Hatt M; Hindié E; Giacchetti S; de Cremoux P; Lehmann-Che J; Martineau A; Marty M; Cuvier C; Cheze-Le Rest C; de Roquancourt A; Visvikis D; Espié M
    Cancer; 2013 Jun; 119(11):1960-8. PubMed ID: 23504954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment.
    Groheux D; Giacchetti S; Hatt M; Marty M; Vercellino L; de Roquancourt A; Cuvier C; Coussy F; Espié M; Hindié E
    Br J Cancer; 2013 Sep; 109(5):1157-64. PubMed ID: 23942075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early prediction of pathological complete response in luminal B type neoadjuvant chemotherapy-treated breast cancer patients: comparison between interim 18F-FDG PET/CT and MRI.
    Pahk K; Kim S; Choe JG
    Nucl Med Commun; 2015 Sep; 36(9):887-91. PubMed ID: 25932536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.